Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$21.11 USD

21.11
286,083

-0.47 (-2.16%)

Updated Apr 22, 2024 11:55 AM ET

After-Market: $21.83 +0.73 (3.44%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Intellia Therapeutics, Inc. (NTLA) Price Targets

Average Price Target Highest Price Target Lowest Price Target Upside to Average Price Target
$73.70 $144.00 $29.00 241.68%

Price Target

Based on short-term price targets offered by 23 analysts, the average price target for Intellia Therapeutics, Inc. comes to $73.70. The forecasts range from a low of $29.00 to a high of $144.00. The average price target represents an increase of 241.68% from the last closing price of $21.57.

Analyst Price Targets (23)

Last Close 21.57
Average 73.70 241.68% Upside Low 29.00 34.45% Upside High 144.00 567.59% Upside

Broker Rating

Intellia Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 1.54 a month ago based on 26 recommendations.

Of the 26 recommendations deriving the current ABR, 18 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 69.23% and 7.69% of all recommendations. A month ago, Strong Buy made up 69.23%, while Buy represented 7.69%.

Broker Rating Breakdown

Broker Rating Visualization

Brokerage Recommendations

Today 1 Week Ago 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 18 18 18 19 19
Buy 2 2 2 2 2
Hold 6 6 6 5 4
Sell 0 0 0 0 0
Strong Sell 0 0 0 0 0
ABR 1.54 1.54 1.54 1.46 1.40

1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.

2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.

Analyst Upgrades/Downgrades

Date Brokerage Firm Analyst Previous Current
3/1/2024 Chardan Capital Markets Yevgeniya Livshits Strong Buy Strong Buy
2/27/2024 Truist Securities Joon Lee Strong Buy Strong Buy
2/23/2024 Canaccord Genuity Whitney Ijem Strong Buy Strong Buy
2/15/2024 Wedbush Securities David M Nierengarten Hold Hold
1/2/2024 Robert W. Baird & Co. Jack K Allen Hold Hold
11/13/2023 Cantor Fitzgerald & Co Rick Bienkowski Strong Buy Strong Buy
11/10/2023 Raymond James Steven Seedhouse Moderate Buy Moderate Buy
11/10/2023 BMO Capital Markets Kostas Biliouris Strong Buy Strong Buy
11/9/2023 William Blair Myles R Minter Strong Buy Strong Buy
11/9/2023 SVB Securities Mani Foroohar Strong Buy Strong Buy
11/3/2023 Brookline Capital Markets Leah R Cann Strong Buy Strong Buy
8/7/2023 JMP Securities Silvan C Tuerkcan Hold Hold

1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.

2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.

Average Brokerage Rating

Current ABR

Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for most of the leading investment web sties. The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc) made by the brokerage firms for a given stock.

ABR vs Zacks Rank

 1.54
ABR (Last week) 1.54
# of Recs in ABR 26
Average Target Price $73.70
LT Growth Rate 29.30%
Industry Medical - Biomedical and Genetics
Industry Rank by ABR 86 of 252
Current Quarter EPS Est: -1.34